IMAB - I-Mab
I-Mab Logo

IMAB - I-Mab

https://www.i-mabbiopharma.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

I-Mab, a clinical-stage biopharmaceutical company, discovers, develops and markets biologics to treat cancer and autoimmune disorders. The company is headquartered in Shanghai, the People's Republic of China.

52W High
$5.90
52W Low
$0.60
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.37
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.14
EV/Revenue (<3 favorable)
0.99
P/S (TTM) (<3 favorable)
25.39
P/B (<3 favorable)
1.82
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
21.43%
Institutions (25–75% balanced)
20.00%
Shares Outstanding
81,660,000
Float
97,607,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
3,492,100
Gross Profit (TTM)
41,594,000
EPS (TTM)
-0.51
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.17%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.62
Momentum
Bearish momentum
Value
0.1632
Previous
0.2020
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025